Phase 1 Study Finds Similar PK Between Eculizumab Biosimilar, Soliris

August 13, 2022

A phase 1 study compared pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity between SB12, a proposed eculizumab biosimilar, and EU and US reference products (Soliris) in healthy adults.

The Top 5 Biosimilar Articles for the Week of August 8

August 12, 2022

Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics

August 11, 2022

Prospective Study Finds Adalimumab Biosimilars Effective in IBD, but Fall Short of Infliximab Product

August 10, 2022

Review: Biosimilar-to-Biosimilar Switching Is Safe, Effective

August 09, 2022

Featured Content

How Biosimilars Are Making Big Pharma More Eco-Friendly

As drug companies continue to follow the growing trend adopting more environmentally friendly and socially conscious frameworks, many are choosing to highlight their biosimilar portfolios as an example of their efforts.

Biosimilars Oncology Roundup for July 2022—Podcast Edition

We recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.

Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains

Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, breaks down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.

$35 Insulin Cap for Private Sector Blocked From Budget Reconciliation Bill

August 8th 2022

By Skylar Jeremias

Article

While efforts to cap monthly insulin costs for Medicare patients at $35 survived a budget reconciliation bill in the Senate, Republicans blocked the measure from extending to the private sector.

Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition

August 7th 2022

By Skylar Jeremias

Podcast

On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.

Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains

August 6th 2022

By The Center for Biosimilars Staff

Article

In an interview with The Center for Biosimilars®, Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, breaks down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.

The Top 5 Biosimilar Articles for the Week of August 1

August 5th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of August 1, 2022.

BLA Accepted for Fresenius Kabi Tocilizumab Biosimilar

August 4th 2022

By The Center for Biosimilars

Article

In a statement, Fresenius Kabi officials said the company is rapidly expanding its portfolio in autoimmune and oncology conditions.

FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab

August 3rd 2022

By The Center for Biosimilars

Article

Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention of the prescribing clinician.

Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023

August 2nd 2022

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.

Biosimilars Oncology Roundup: July 2022

August 1st 2022

By Skylar Jeremias

Article

Trials for denosumab biosimilars are ramping up and researchers are concerned whether patients with cancer switching to biosimilars have been adequately informed beforehand.

Organon's Jim Carey Shares Thoughts on Biosimilar Legislation, Emerging Adalimumab Products

July 31st 2022

By Skylar Jeremias

Article

Jim Carey, head of US Policy and Government Relations at Organon, a spinoff company from Merck, breaks down strategies to push forward biosimilar legislation, the anticipation for adalimumab biosimilars, and more in this multi-part interview.

Denosumab Biosimilar Demonstrates Noninferiority to Prolia in Postmenopausal Osteoporosis

July 30th 2022

By Deana Ferreri, PhD

Article

Results from a phase 3 trial suggested similar efficacy and safety of the denosumab biosimilar candidate Arylia (AryoGen Pharmed) to the reference product (Prolia) in postmenopausal osteoporosis.